Volume 28, Issue 150, August 2024

Trends of HBA1c and related side effects of dapagliflozin 10mg and semaglutide 1mg in adults with type 2 diabetes mellitus in King Abdulaziz Medical City, Riyadh, Saudi Arabia

Khalid Alharbi^1♦, Eman Alharbi², Bader Altulaihi³, Meshal Alhadlaq¹, Ali Alqobaisi¹, Khaled Alkhudhairi¹

¹Resident at Family Medicine Department, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia
²Diabetes Clinical Fellow at University Diabetes Center, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia
³Consultant, Family Medicine Department, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia

^♦Corresponding Author
Resident at Family Medicine Department, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia

ABSTRACT

Diabetes is a common disease characterized by impaired glycemic control in the body. High blood glucose readings are any fasting blood glucose more than or equal to 126 mg/dl, random blood glucose more than or equal to 200 mg/dl, or A1c level greater than or equal to 6.5%. We used a retrospective, chart review study design to collect the A1c readings in patients using Dapagliflozin 10mg. The total sample size was 107 participants. 57 participants were on Dapagliflozin, 33 on Semaglutide, and 17 were on a combination of Semaglutide and Dapagliflozin. Weight significantly decreased in participants using Dapagliflozin and Semaglutide combination (p<0.001) compared to those using Semaglutide alone (p<0.001). Additionally, HbA1c significantly decreased among participants using Dapagliflozin and Semaglutide (p<0.001) and those using Dapagliflozin alone (p<0.001). Even though SGLT-2 inhibitors weakly reduce HbA1c, we have found in our study that Dapagliflozin has significantly decreased A1c in addition to a reduction in weight especially among females.

Keywords: Type 2 diabetes mellitus, hba1c, semaglutide, dapagliflozin, sglt-2 inhibitors

Medical Science, 2024, 28, e103ms3406

PDF

DOI: https://doi.org/10.54905/disssi.v28i150.e103ms3406

Published: 16 August 2024